Pfizer and biontech receive health canada authorization for xbb.1.5-adapted monovalent covid-19 vaccine

Kirkland, quebec and mainz, germany, september 28, 2023 — pfizer canada ulc and biontech se (nasdaq: bntx, “biontech”) announced today that health canada has authorized the companies' omicron xbb.1.5-adapted monovalent covid-19 vaccine (comirnaty® omicron xbb.1.5) for ages 6 months and older. the updated vaccine will be available in canada as a single dose for individuals 5 years of age and older, regardless of prior covid-19 vaccination history. for children 6 months through 4 years of age the updated vaccine is authorized for administration as a three-dose series in those without a history of completion of a covid-19 primary vaccination course, or as a single dose for those with a history of completion of a covid-19 primary vaccination course.
BNTX Ratings Summary
BNTX Quant Ranking